AR015973A1 - Uso de oxido nitrico gaseoso para la manufactura de un medicamento para disminuir y prevenir el dano por isquemia-reperfusion no pulmonar en un mamifero - Google Patents

Uso de oxido nitrico gaseoso para la manufactura de un medicamento para disminuir y prevenir el dano por isquemia-reperfusion no pulmonar en un mamifero

Info

Publication number
AR015973A1
AR015973A1 ARP980105231A ARP980105231A AR015973A1 AR 015973 A1 AR015973 A1 AR 015973A1 AR P980105231 A ARP980105231 A AR P980105231A AR P980105231 A ARP980105231 A AR P980105231A AR 015973 A1 AR015973 A1 AR 015973A1
Authority
AR
Argentina
Prior art keywords
ischemia
reperfusion
decrease
mammal
nitric oxide
Prior art date
Application number
ARP980105231A
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26742873&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR015973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of AR015973A1 publication Critical patent/AR015973A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de oxido nítrico gaseoso para la manufactura de un medicamento para disminuir o prevenir el dano por isquemia-reperfusion no pulmonar en un mamífero,que comprende: una cantidad terapéuticamente efectiva de oxido nítrico gaseoso suficiente como para disminuir la capacidad de los leucocitos o plaquetas delmamífero para activarse de manera tal que contribuya con un proceso inflamatorio en el sitio de la isquemia-reperfusion en el tejido no pulmonar, disminuyendoasí o previniendo el dano por isquemia-reperfusion no pulmonar en el mamífero y un segundo compuesto que potencia el efecto terapéutico del oxido nítricogaseoso y un vehículo farmacéuticamente aceptable. Esto se destina para identificar a un mamífero que tiene isquemia -reperfusiono corre el riesgo dedesarrollar isquemia-reperfusion en un tejido no pulmonar, y hacer que el mamífero inhale una cantidad terapéuticamente efectiva de oxido nítrico gaseososuficiente como para disminuir la capacidad de los leucocitos o plaquetas para activarse de manera tal que contribuyan con el proceso inflamatorio en el sitiode la isquemia-reperfusion o inflamacion en el tejido no pulmonar. Puede administrarse un segundo compuesto que potencia el efecto terapéutico del oxidonítrico gaseoso,junto con el oxido nítrico gaseoso.
ARP980105231A 1997-10-21 1998-10-20 Uso de oxido nitrico gaseoso para la manufactura de un medicamento para disminuir y prevenir el dano por isquemia-reperfusion no pulmonar en un mamifero AR015973A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6292697P 1997-10-21 1997-10-21
US08/971,003 US6656452B1 (en) 1997-10-21 1997-11-14 Use of inhaled NO as anti-inflammatory agent

Publications (1)

Publication Number Publication Date
AR015973A1 true AR015973A1 (es) 2001-05-30

Family

ID=26742873

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105231A AR015973A1 (es) 1997-10-21 1998-10-20 Uso de oxido nitrico gaseoso para la manufactura de un medicamento para disminuir y prevenir el dano por isquemia-reperfusion no pulmonar en un mamifero

Country Status (13)

Country Link
US (2) US6656452B1 (es)
EP (1) EP1073416B1 (es)
JP (1) JP2003532615A (es)
AR (1) AR015973A1 (es)
AT (1) ATE421874T1 (es)
AU (1) AU751853B2 (es)
CA (1) CA2309038C (es)
CY (1) CY1110228T1 (es)
DE (1) DE69840526D1 (es)
DK (1) DK1073416T3 (es)
ES (1) ES2319240T3 (es)
PT (1) PT1073416E (es)
WO (1) WO1999020251A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
US20030070674A1 (en) * 2001-10-12 2003-04-17 Bryan Perry Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US7086397B2 (en) * 2002-02-16 2006-08-08 Graham Lindley Spruiell Patient usable emergency medical kit
WO2003101276A2 (en) * 2002-05-22 2003-12-11 Virginia Commonwealth University Protective effects of pde-5 inhibitors
AU2003245934A1 (en) * 2002-06-12 2003-12-31 Messer Griesheim Gmbh Anti-spasmodic comprising xenon
EA200500062A1 (ru) * 2002-06-21 2005-06-30 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Фармацевтическое применение оксида азота, гемоксигеназы-1 и продуктов деградации гема
SE0300971D0 (sv) * 2003-04-03 2003-04-03 Aga Ab Nitric oxide in treatment of inflammation
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
EP2099463B1 (en) * 2006-11-07 2014-07-16 The General Hospital Corporation Attenuation of vasoactive oxygen carrier-induced vasoconstriction
CA2685446A1 (en) 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
WO2010049423A1 (en) * 2008-10-27 2010-05-06 Life Sciences Research Partners Vzw Effects of nitric oxide inhalation on long-term myocardial reperfusion injury
DK2440239T3 (en) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
JP5581500B2 (ja) * 2010-03-10 2014-09-03 学校法人北里研究所 虚血再灌流障害軽減用治療剤および治療装置
EP2645860A4 (en) * 2010-12-03 2014-07-09 Geno Llc NITROGEN OXIDE TREATMENTS
EP2763935B2 (en) 2011-10-03 2023-06-07 NitricGen, Inc. Apparatus and method for generating nitric oxide in controlled and accurate amounts
US9572833B2 (en) 2011-11-07 2017-02-21 The General Hospital Corporation Treatment of red blood cells
JP2014141536A (ja) * 2014-05-16 2014-08-07 Kitasato Institute 虚血再灌流障害軽減用治療剤および治療装置
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2023190532A1 (ja) * 2022-03-29 2023-10-05 康太郎 木田 横紋筋融解症を治療するための医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0560928T3 (da) * 1990-12-05 1997-12-01 Gen Hospital Corp Anordninger til behandling af pulmonal vasokonstriktion og astma
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
GB9320978D0 (en) 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
ES2149338T3 (es) 1993-11-02 2000-11-01 Us Health Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.
US5521191A (en) 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5725492A (en) * 1996-03-04 1998-03-10 Cormedics Corp Extracorporeal circulation apparatus and method
WO1997037644A1 (en) 1996-04-05 1997-10-16 The General Hospital Corporation Treatment of a hemoglobinopathy
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation

Also Published As

Publication number Publication date
US20040096523A1 (en) 2004-05-20
EP1073416B1 (en) 2009-01-28
AU751853B2 (en) 2002-08-29
US6811768B2 (en) 2004-11-02
EP1073416A1 (en) 2001-02-07
CA2309038C (en) 2009-04-21
JP2003532615A (ja) 2003-11-05
CA2309038A1 (en) 1999-04-29
ATE421874T1 (de) 2009-02-15
ES2319240T3 (es) 2009-05-05
DE69840526D1 (de) 2009-03-19
DK1073416T3 (da) 2009-03-09
EP1073416A4 (en) 2004-07-07
PT1073416E (pt) 2009-03-17
CY1110228T1 (el) 2015-01-14
WO1999020251A1 (en) 1999-04-29
US6656452B1 (en) 2003-12-02
AU1101299A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
AR015973A1 (es) Uso de oxido nitrico gaseoso para la manufactura de un medicamento para disminuir y prevenir el dano por isquemia-reperfusion no pulmonar en un mamifero
ES2365639T3 (es) Ectoína para el tratamiento de fugas vasculares.
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
JP2022180461A5 (es)
TR200102110T2 (tr) Astım için formoterol ve flütikazon propiyonat kombinasyonları.
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
CO5550426A2 (es) Novedoso metodo terapeutico
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
AR063109A1 (es) Terapias topicas para la mucositis oral y otras afecciones
EA200500804A1 (ru) Топические противоинфекционные композиции
AR031348A1 (es) Inhalacion de oxido nitrico
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
ES2927803T3 (es) Curación de heridas mediante la movilización de células madre autólogas
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
Corbellari et al. The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors
RU2007138263A (ru) Противовоспалительные соединения
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona

Legal Events

Date Code Title Description
FB Suspension of granting procedure